Literature DB >> 1706769

A capture enzyme immunoassay for detection of HIV-2/SIV antigen.

R Thorstensson1, L Walther, P Putkonen, J Albert, G Biberfeld.   

Abstract

An antigen capture enzyme immunoassay was developed for the demonstration of human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus (SIV). The assay (HIV-2 CE) has a sensitivity of approximately 250 pg/ml of HIV-2/SIV antigen. The HIV-2 CE was 4-16 times more sensitive than the Abbott HIV-1 antigen assay for detection of HIV-2/SIV antigen in cell culture supernatant. The sensitivity for detection of HIV-2/SIV antigen in serum or plasma was 98.5% in the HIV-2 CE and 95.5% in the Abbott HIV-1 antigen assay. The specificity of the HIV-2 CE was 99.2% (one false positive among 119 negative sera) whereas the Abbott assay was 100% specific. The HIV-2 CE detected antigen in supernatants from cultures of peripheral blood mononuclear cells of macaque monkeys infected with HIV-2 or SIV about 1 week before a reverse transcriptase (RT) microassay was positive and remained positive for at least 1 week after the RT assay had become negative. Three cultures from persistently infected monkeys were positive only in the HIV-2 CE, reflecting a higher sensitivity compared to the RT microassay. Thus, the HIV-2 CE was more sensitive than the Abbott HIV-1 antigen assay for detection of HIV-2/SIV antigen in culture supernatants as well as in serum/plasma. Furthermore, the HIV-2 CE showed a higher sensitivity than the RT microassay for detection of HIV-2/SIV in cell culture supernatants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706769

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  8 in total

1.  Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge.

Authors:  R K S Ahmed; B Makitalo; K Karlen; C Nilsson; G Biberfeld; R Thorstensson
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

2.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors:  E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  Characterization of a monoclonal anti-capsid antibody that cross-reacts with three major primate lentivirus lineages.

Authors:  Brigitte E Sanders-Beer; Magdalena Eschricht; Janna Seifried; Vanessa M Hirsch; Jonathan S Allan; Stephen Norley
Journal:  Virology       Date:  2011-12-05       Impact factor: 3.616

5.  Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Authors:  K Uberla; C Stahl-Hennig; D Böttiger; K Mätz-Rensing; F J Kaup; J Li; W A Haseltine; B Fleckenstein; G Hunsmann; B Oberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

6.  Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.

Authors:  A Mörner; A Björndal; J Albert; V N Kewalramani; D R Littman; R Inoue; R Thorstensson; E M Fenyö; E Björling
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Authors:  Qin Lizeng; Charlotta Nilsson; Samer Sourial; Sören Andersson; Olav Larsen; Peter Aaby; Mariethe Ehnlund; Ewa Björling
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  HIV-2 neutralization by intact V3-specific Fab fragments.

Authors:  Samer Sourial; Charlotta Nilsson
Journal:  Virol J       Date:  2008-08-18       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.